Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis

Miller, P.D., Bilezikian, J.P., Fitzpatrick, L.A. et al. (4 more authors) (2020) Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. Current Medical Research and Opinion. ISSN 0300-7995

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
Keywords: Abaloparatide; osteoporosis; vertebral fracture; nonvertebral fracture; anabolic
Dates:
  • Accepted: 15 September 2020
  • Published (online): 12 October 2020
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 27 Oct 2020 16:00
Last Modified: 27 Oct 2020 16:00
Status: Published online
Publisher: Informa UK Limited
Refereed: Yes
Identification Number: https://doi.org/10.1080/03007995.2020.1824897
Related URLs:

Share / Export

Statistics